Riociguat for the Treatment of Pulmonary Arterial Hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853

Bosentan Therapy for Pulmonary Arterial Hypertension

Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359

Inhaled Iloprost for Severe Pulmonary Hypertension

Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393

Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing

Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

White, R. J., Noordegraaf, A. V., Rosenkranz, S., Oudiz, R. J., McLaughlin, V. V., Hoeper, M. M., Grünig, E., Ghofrani, H. A., Chakinala, M. M., Barberà, J. A., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1180-1 · Cited by 18

The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats

Reinke, Y., Groß, S., Eckerle, L. G., Hertrich, I., Busch, M., Busch, R., Riad, A., Rauch, B. H., Stasch, J., Dörr, M., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.022 · Cited by 18

Riociguat for the treatment of pulmonary hypertension

Hambly, N., & Granton, J. T. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1106316 · Cited by 19

The limits of oral therapy in pulmonary arterial hypertension management

Jing, Z., & Liu, Q. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s49026 · Cited by 18

Pulmonary Arterial Hypertension

Goel, K., Hon, S. M., Farber, H. W., & George, M. P. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.010 · Cited by 18

International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension

Sahay, S., Visovatti, S., Tonelli, A. R., Villasmil, N., Austin, E. D., Badagliacca, R., Berger, R. M. F., Boucly, A., Chen, Y., Church, C., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.04.015 · Cited by 17

The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges

Swisher, J. W., & Weaver, E. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s321025 · Cited by 17

Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension

Luo, T., Wu, H., Zhu, W., Zhang, L., Huang, Y., & Yang, X. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107631 · Cited by 17

The Influence of Nitric Oxide on Soluble Guanylate Cyclase Regulation by Nucleotides

Sürmeli, N. B., Müskens, F. M., & Marletta, M. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641431 · Cited by 18

Therapeutic options in pulmonary hepatic vascular diseases

Horvatits, T., & Fuhrmann, V. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.857598 · Cited by 17

Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?

Koress, C. M., Swan, K. W., & Kadowitz, P. J. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0645-6 · Cited by 17

Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials

Gao, X., Zhang, J., Jiang, X., Ge, Z., Wang, Z., Li, B., Mao, W., & Chen, S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s133288 · Cited by 17

Important role of endothelium-dependent hyperpolarization in the pulmonary microcirculation in male mice: implications for hypoxia-induced pulmonary hypertension

Tanaka, S., Shiroto, T., Godo, S., Saito, H., Ikumi, Y., Ito, A., Kajitani, S., Sato, S., & Shimokawa, H. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00487.2017 · Cited by 17

Novel Insights and Treatment Strategies for Right Heart Failure

Lin, W., Poh, A.-L., & Tang, W. H. W. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0389-5 · Cited by 17

Redox Switches Controlling Nitric Oxide Signaling in the Resistance Vasculature and Implications for Blood Pressure Regulation: Mid-Career Award for Research Excellence 2020

Dosunmu-Ogunbi, A. M., Galley, J. C., Yuan, S. S., Schmidt, H. M., Wood, K. C., & Straub, A. C. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.16493 · Cited by 19

Biomarkers in Pulmonary Arterial Hypertension

Rosenthal, J., & Jacob, M. S. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0225-5 · Cited by 17

Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator

Watanabe, H. (2018) · European Cardiology Review · doi:10.15420/ecr.2017:22:2 · Cited by 17

Open Transapical Approach to Transcatheter Paravalvular Leakage Closure

Nijenhuis, V. J., Swaans, M. J., Post, M. C., Heijmen, R. H., de Kroon, T. L., & ten Berg, J. M. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.113.001171 · Cited by 17

Non-canonical chemical feedback self-limits nitric oxide-cyclic GMP signaling in health and disease

Dao, V. T.-V., Elbatreek, M. H., Deile, M., Nedvetsky, P. I., Güldner, A., Ibarra‐Alvarado, C., Gödecke, A., & Schmidt, H. H. H. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-66639-w · Cited by 19

Early progression stage of malignancy of uterine cervical dysplasia as revealed by immunohistochemical demonstration of increased DNA-instability.

Khaled, A., Imamura, Y., Noriki, S., & Fukuda, M. (2000) · PubMed · Cited by 17

PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension

Ramchandran, R., Raghavan, A., Geenen, D. L., Sun, M. R., Bach, L., Yang, Q., & Raj, J. U. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00093.2014 · Cited by 16

Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Mielniczuk, L. M., Swiston, J. R., & Mehta, S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.014 · Cited by 16

A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy

Ataya, A., Cope, J. M., & Alnuaimat, H. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5120114 · Cited by 16

Effects of Riociguat on Right Ventricular Remodelling in Chronic Thromboembolic Pulmonary Hypertension Patients: A Prospective Study

Ahmadi, A., Thornhill, R. E., Peña, E., Renaud, J. M., Promislow, S., Chandy, G., Davies, R. A., Stewart, D. J., Contreras-Domínguez, V., Dunne, R., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.06.007 · Cited by 16

Phosphodiesterase expression in the normal and failing heart

Li, E. A., Wang, X., Han, Y. S., & Brozovich, F. V. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.12.013 · Cited by 16

Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis

Duca, F., Snidat, A., Binder, C., Rettl, R., Dachs, T.-M., Seirer, B., Ligios, L. C., Dusik, F., Capelle, C. D. J., Hong, Q., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041093 · Cited by 16

Repurposing of medications for pulmonary arterial hypertension

Toshner, M. R., Spiekerkoetter, E. F., Bogaard, H. J., Hansmann, G., Nikkho, S. M., & Prins, K. W. (2020) · Pulmonary Circulation · doi:10.1177/2045894020941494 · Cited by 17

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities

Barnikel, M., Kneidinger, N., Arnold, P., Waelde, A., Behr, J., & Milger, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11041084 · Cited by 16

Profiles and Treatment Patterns of Patients with Pulmonary Arterial Hypertension on Monotherapy at Experienced Centres

Wißmüller, M., Xanthouli, P., Benjamin, N., Grünig, E., Richter, M. J., Gall, H. J., Ghofrani, H. A., Herkenrath, S. D., Skowasch, D., Pizarro, C., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13804 · Cited by 16

Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells

Romano, E., Rosa, I., Fioretto, B. S., Giuggioli, D., Manetti, M., & Matucci‐Cerinic, M. (2022) · Rheumatology · doi:10.1093/rheumatology/keac433 · Cited by 16

Recent Advances in the Treatment of Pulmonary Arterial Hypertension

Otani, N., Tomoe, T., Kawabe, A., Sugiyama, T., Horie, Y., Sugimura, H., Yasu, T., & Nakamoto, T. (2022) · Pharmaceuticals · doi:10.3390/ph15101277 · Cited by 16

Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future

Fike, C. D., & Aschner, J. L. (2023) · Pharmaceuticals · doi:10.3390/ph16040503 · Cited by 16

2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.

Hsu, C., Ho, W.-J., Huang, W.-C., Chiu, Y.-W., Hsu, T., Kuo, P., Hsu, H., Chang, J., Cheng, C., Lai, C., et al. (2014) · Europe PMC (PubMed Central) · Cited by 16

Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study

D’Armini, A. M., Ghofrani, H. A., Kim, N. H., Mayer, E., Morsolini, M., Pulido, T., Simonneau, G., Wilkins, M. R., Curram, J., Davie, N. J., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.02.003 · Cited by 16

Absorption of Riociguat (BAY 63‐2521): Bioavailability, Food Effects, and Dose Proportionality

Becker, C., Frey, R., Hesse, C., Unger, S., Reber, M., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685018 · Cited by 16

Riociguat improves health‐related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study

Sood, N., Aranda, A., Platt, D. M., LaRose, A., Kleinjung, F., & O'Brien, G. M. (2018) · Pulmonary Circulation · doi:10.1177/2045894018823715 · Cited by 16

Current status of pulmonary arterial hypertension in Korea

Jang, A. Y., & Chung, W. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.185 · Cited by 16

Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?

Howard, L., Ferrari, P., & Mehta, S. (2014) · European Respiratory Review · doi:10.1183/09059180.00007514 · Cited by 16

Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations

Seyfarth, H., Gille, J., Sablotzki, A., Gerlach, S., Malcharek, M. J., Gosse, A., Gahr, R., & Czeslick, E. G. (2015) · Europe PMC (PubMed Central) · doi:10.3205/iprs000062 · Cited by 16

Medical therapies for pulmonary arterial hypertension

Pulido, T., Zayas, N., Mendieta, M. A.-D., Plascencia, K., & Escobar, J. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9527-x · Cited by 16

Eisenmenger syndrome: current perspectives

Nashat, H., Kempny, A., McCabe, C., Price, L., Harries, C., Alonso-González, R., Gatzoulis, M. Α., Wort, S. J., & Dimopoulos, K. (2017) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s117838 · Cited by 16

The sGC activator inhibits the proliferation and migration, promotes the apoptosis of human pulmonary arterial smooth muscle cells via the up regulation of plasminogen activator inhibitor-2

Zhang, S., Zou, L., Yang, T., Yang, Y., Zhai, Z., Xiao, F., & Wang, C. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.02.006 · Cited by 15

Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis

Zhang, H., Zhang, R., Jiang, X., Sun, K., Wu, D., & Jing, Z. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.04.003 · Cited by 15

Pulmonary Arterial Hypertension

Patel, B. B., Feng, Y., & Cheng-Lai, A. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000042 · Cited by 15

Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Hill, N. S., Rahaghi, F., Sood, N., Frey, R., & Ghofrani, H. A. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.005 · Cited by 15

Replacing a phosphodiesterase‐5 inhibitor with riociguat in patients with connective tissue disease‐associated pulmonary arterial hypertension: a case series

Raina, A., Benza, R. L., & Farber, H. W. (2017) · Pulmonary Circulation · doi:10.1177/2045893217721694 · Cited by 15

Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management

Papamichalis, M., Xanthopoulos, A. V., Papamichalis, P. A., Skoularigis, J. S., & Triposkiadis, F. K. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09847-5 · Cited by 15

Cancer and pulmonary hypertension: Learning lessons and real-life interplay

Pullamsetti, S. S., Nayakanti, S. R., Chelladurai, P., Mamazhakypov, A., Mansouri, S., Savai, R., & Seeger, W. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2020.10 · Cited by 15

Portopulmonary Hypertension: A Review of the Current Literature

Peppas, S., Nagraj, S., Koutsias, G., Kladas, M., Barakakis, P. A., Schizas, D., Giannakoulas, G. A., Palaiodimos, L., & Kokkinidis, D. G. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.04.056 · Cited by 15

Pathogenic Mechanisms of Pulmonary Arterial Hypertension

Zhu, J., Yang, L., Jia, Y., Balistrieri, A., Fraidenburg, D. R., Wang, J., Tang, H., & Yuan, J. X. ‐. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.09.010 · Cited by 15

LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4

Shen, M., Zheng, C., Chen, L., Li, M., Huang, X., He, M., Liu, C.-Y., Lin, H., Liao, W., Bin, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114569 · Cited by 15

MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH

Kolditz, M., Seyfarth, H., Wilkens, H., Ewert, R., Bollmann, T., Dinter, C., Hertel, S., Klose, H. F. E., Opitz, C. F., Grünig, E., et al. (2015) · Lung · doi:10.1007/s00408-015-9802-y · Cited by 15

Oral Administration of Soluble Guanylate Cyclase Agonists to Rats Results in Osteoclastic Bone Resorption and Remodeling with New Bone Formation in the Appendicular and Axial Skeleton

Homer, B. L., Morton, D. G., Bagi, C. M., Warneke, J. A., Andresen, C. J., Whiteley, L. O., Morris, D. L., & Tones, M. A. (2014) · Toxicologic Pathology · doi:10.1177/0192623314546559 · Cited by 15

Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck

Ansara, A. J., Kolanczyk, D. M., & Koehler, J. M. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12363 · Cited by 15

Pulmonary hypertension associated with lung diseases and hypoxemia

Cuttica, M. J. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9551-x · Cited by 15

Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data

White, R. J., & Rao, Y. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0274le · Cited by 15

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension

Davey, R., Benza, R. L., Murali, S., & Raina, A. (2017) · Pulmonary Circulation · doi:10.1177/2045893217708566 · Cited by 15

NO‐sensitive guanylyl cyclase in the lung

Friebe, A., & Englert, N. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15345 · Cited by 15

Multidrug resistance proteins preferentially regulate natriuretic peptide‐driven cGMP signalling in the heart and vasculature

Grange, R. M. H., Preedy, M. E. J., Renukanthan, A., Dignam, J. P., Lowe, V., Moyes, A. J., Pérez‐Ternero, C., Aubdool, A. A., Baliga, R. S., & Hobbs, A. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15593 · Cited by 15

The heart and pulmonary arterial hypertension in systemic sclerosis

Vandecasteele, E. H., Pauw, M. D., Brusselle, G., Decuman, S., Piette, Y., Keyser, F. D., & Smith, V. M. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2015.1108538 · Cited by 15

Pathophysiology of Pulmonary Arterial Hypertension: Focus on Vascular Endothelium as a Potential Therapeutic Target

Correale, M., Mercurio, V., Bevere, E. M. L., Pezzuto, B., Tricarico, L., Attanasio, U., Raucci, A., Ferrara, A. L., Loffredo, S., Puteo, C., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199631 · Cited by 14

Systemic sclerosis: pathogenic mechanisms and their implications for treatment

Lescoat, A., Lecureur, V., Gudjonsson, J. E., & Khanna, D. (2025) · Seminars in Immunopathology · doi:10.1007/s00281-025-01065-6 · Cited by 14

Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis

Erdoğan, M., Esatoğlu, S. N., Avcı, B. K., & Hatemi, G. (2024) · Internal and Emergency Medicine · doi:10.1007/s11739-024-03539-1 · Cited by 14

Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis

Badiani, B., & Messori, A. (2015) · Heart Lung and Circulation · doi:10.1016/j.hlc.2015.05.020 · Cited by 14

Pharmacodynamic considerations in the treatment of pulmonary hypertension in infants: challenges and future perspectives

Kraemer, U., Otter, S. C. M. C.-D., Snoek, K. G., & Tibboel, D. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1116520 · Cited by 14

Bioavailability, Pharmacokinetics, and Safety of Riociguat Given as an Oral Suspension or Crushed Tablet with and without Food

Saleh, S., Frey, R., Becker, C., Unger, S., Wensing, G., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685020 · Cited by 14

Update on pharmacotherapy for pulmonary hypertension

Prior, D., Adams, H. S. L., & Williams, T. J. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00468 · Cited by 14

Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease

Kozij, N. K., Granton, J. T., Silkoff, P. E., Thenganatt, J., Chakravorty, S., & Johnson, S. R. (2017) · Canadian Respiratory Journal · doi:10.1155/2017/6736239 · Cited by 14

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences

Andersen, A., Korsholm, K., Mellemkjær, S., & Nielsen‐Kudsk, J. E. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.06.005 · Cited by 14

Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study

Al‐Naamani, N., Pan, H., Anderson, M. R., Torigian, D. A., Tong, Y., Oyster, M. L., Porteous, M. K., Palmer, S. M., Arcasoy, S. M., Diamond, J. M., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-247oc · Cited by 14

Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension

Kenny, M., Clarke, M. M., & Pogue, K. T. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020961291 · Cited by 14

Chronic thromboembolic pulmonary hypertension: a review

Chong, C., Tay, E. L., Sia, C., & Poh, K. K. (2021) · Singapore Medical Journal · doi:10.11622/smedj.2021089 · Cited by 14

The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling

Devendran, A. S., Kar, S., Bailey, R. A., & Trivieri, M. G. (2022) · Cells · doi:10.3390/cells11233823 · Cited by 16

Novel and emerging therapies in pulmonary arterial hypertension

Cassady, S. J., Soldin, D., & Ramani, G. V. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1022971 · Cited by 14

Targeted Therapy Is Required for Management of Pulmonary Arterial Hypertension After Defect Closure in Adult Patients With Atrial Septal Defect and Associated Pulmonary Arterial Hypertension

Fujino, T., Yao, A., Hatano, M., Inaba, T., Muraoka, H., Minatsuki, S., Imamura, T., Maki, H., Kinugawa, K., Ōno, M., et al. (2015) · International Heart Journal · doi:10.1536/ihj.14-183 · Cited by 14

Population Pharmacokinetics of Single‐Dose Riociguat in Patients with Renal or Hepatic Impairment

Saleh, S., Becker, C., Frey, R., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685647 · Cited by 14

Pharmacokinetic Interaction Study between Riociguat and the Combined Oral Contraceptives Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women

Frey, R., Unger, S., van der Mey, D., Becker, C., Saleh, S., Wensing, G., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685428 · Cited by 14

Population Pharmacokinetics and the Pharmacokinetic/Pharmacodynamic Relationship of Riociguat in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Saleh, S., Becker, C., Frey, R., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685404 · Cited by 14

Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

Moriarty, J. M., Khan, S. N., Kao, S. D., & Saggar, R. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-2012-2 · Cited by 14

Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review

Puk, O., Nowacka, A., Smulewicz, K., Mocna, K., Bursiewicz, W., Kęsy, N., Kwiecień, J., & Wiciński, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112592 · Cited by 14

Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis

Valenzuela, A., Nandagopal, S., Steen, V. D., & Chung, L. S. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.04.009 · Cited by 14

Vericiguat in Heart Failure with Reduced Ejection Fraction

Armstrong, P. W., Anstrom, K. J., & O'Connor, C. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027731 · Cited by 14

Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review

Gu, Z., Zhang, C., Wei, A., Cui, M., Pu, J., Lin, H., & Liu, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-16349-7 · Cited by 13

Pulmonary Vasodilator Therapy in Persistent Pulmonary Hypertension of the Newborn

Sharma, M., Callan, E., & Konduri, G. G. (2022) · Clinics in Perinatology · doi:10.1016/j.clp.2021.11.010 · Cited by 13

Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies

Varian, F., Dick, J., Battersby, C., Roman, S. C., Ablott, J., Watson, L., Binmahfooz, S., Zafar, H., Colgan, G., Cannon, J. E., et al. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12337 · Cited by 13

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial

Gladwin, M. T., Gordeuk, V. R., Desai, P. C., Minniti, C. P., Novelli, E. M., Morris, C. R., Ataga, K. I., Castro, L. D., Curtis, S. A., Rassi, F. A. E., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00045-0 · Cited by 14

Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, Vascular Remodeling, and Proliferative-Proinflammatory Gene Expression

Legchenko, E., Chouvarine, P., Qadri, F., Specker, E., Nazaré, M., Wesołowski, R., Matthes, S., Bäder, M., & Hansmann, G. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.04.006 · Cited by 13

Shifting Paradigms in the Management of Pulmonary Hypertension

Pradhan, A. K., Tyagi, R., Sharma, P., Bajpai, J., & Kant, S. (2024) · European Cardiology Review · doi:10.15420/ecr.2024.11 · Cited by 13

Riociguat (BAY 63‐2521) and Aspirin: A Randomized, Pharmacodynamic, and Pharmacokinetic Interaction Study

Frey, R., Reber, M., Krätzschmar, J., Unger, S., Mück, W. M., & Wensing, G. (2016) · Pulmonary Circulation · doi:10.1086/685014 · Cited by 13

Effects of Age and Sex on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat (BAY 63‐2521)

Frey, R., Saleh, S., Becker, C., & Mück, W. M. (2016) · Pulmonary Circulation · doi:10.1086/685019 · Cited by 13

Influence of impaired right ventricular contractile reserve on exercise capacity in patients with precapillary pulmonary hypertension: A study with exercise stress echocardiography

Guo, D., Li, Y., Yang, Y.-H., Zhu, W., Sun, L., Jiang, W., Ye, X., Cai, Q., & Lu, X. (2019) · Echocardiography · doi:10.1111/echo.14283 · Cited by 13

Guanylyl Cyclase-cGMP Signaling Pathway in Melanocytes: Differential Effects of Altered Gravity in Non-Metastatic and Metastatic Cells

Ivanova, K., & Hemmersbach, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031139 · Cited by 13

Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with Pulmonary Hypertension

Murata, M., Kawakami, T., Kataoka, M., Moriyama, H., Hiraide, T., Kimura, M., Endo, J., Kohno, T., Itabashi, Y., & Fukuda, K. (2020) · Cardiology · doi:10.1159/000510860 · Cited by 13

The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials

Sung, S., Yeh, W., Chiang, C., Huang, C., Huang, W., Chen, C.-H., & Cheng, H. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01816-0 · Cited by 13

Inactivation of soluble guanylyl cyclase in living cells proceeds without loss of haem and involves heterodimer dissociation as a common step

Dai, Y., & Stuehr, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15527 · Cited by 15

Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP)

Stollfuß, B., Richter, M. J., Drömann, D., Klose, H. F. E., Schwaiblmair, M., Grünig, E., Ewert, R., Kirchner, M. C., Kleinjung, F., Irrgang, V., et al. (2021) · Journal of Medical Internet Research · doi:10.2196/25163 · Cited by 13

Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study

Benza, R. L., Boucly, A., Farber, H. W., Frost, A., Ghofrani, H.-A., Hoeper, M. M., Lambelet, M., Rahner, C., Bansilal, S., Nikkho, S. M., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.013 · Cited by 13

Repurposing Riociguat to Target a Novel Paracrine Nitric Oxide-TRPC6 Pathway to Prevent Podocyte Injury

Hart, D. C. ‘., Li, J., van der Vlag, J., & Nijenhuis, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212485 · Cited by 13

Cellular Factors That Shape the Activity or Function of Nitric Oxide-Stimulated Soluble Guanylyl Cyclase

Sharina, I. G., & Martin, E. (2023) · Cells · doi:10.3390/cells12030471 · Cited by 14

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial

Distler, O., Allanore, Y., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Pope, J. E., Atsumi, T., Bečvář, R., Czirják, L., HACHULLA, E., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00238-2 · Cited by 13

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

Rubin, L. J., Galiè, N., Grimminger, F., Grünig, E., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Fritsch, A., Menezes, F., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00090614 · Cited by 221

Riociguat for the Treatment of Pulmonary Hypertension: A Meta-analysis of Randomized Controlled Trials

Alrifai, A., Garnet, B., Shah, V., & Lit, L. (2015) · CHEST Journal · doi:10.1378/chest.2281793

Riociguat in Combination With Endothelin Receptor Antagonists (ERAs) for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of PATENT

Hill, N. S., & Sood, N. (2015) · CHEST Journal · doi:10.1378/chest.2281116

September 2013 pulmonary journal club: riociguat; pay the doctor

Robbins, R. (2013) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc116-13

Influence of riociguat treatment on pulmonary arterial hypertension

Zhao, R., & Jiang, Y. (2018) · Herz · doi:10.1007/s00059-018-4697-z · Cited by 8